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The primary benefits of in utero hematopoietic cellular transplantation (IUHCT) arise
from transplanting curative cells prior to the immunologic maturation of the fetus.
However, this approach has been routinely successful only in the treatment of congenital
immunodeficiency diseases that include an inherent NK cell deficiency despite the
existence of normal maternal immunity in either setting. These observations raise the
possibility that fetal NK cells function as an early barrier to allogeneic IUHCT. Herein, we
summarize the findings of previous studies of prenatal NK cell allospecific tolerance in
mice and in humans. Cumulatively, this new information reveals the complexity of the
fetal immune response in the setting of rejection or tolerance and illustrates the role for
fetal NK cells in the final endorsement of allospecific prenatal tolerance.
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In utero hematopoietic cellular transplantation (IUHCT) remains a promising intervention for
treatment of a wide variety of congenital disease (Merianos et al., 2008). A primary assumption
in IUHCT is that the early-gestation fetus has an immature immune system that is incapable of
rejecting a donor cell transplant. As a result, the introduction of donor antigen prior to the devel-
opment of the adaptive immunity should lead to life-long donor-speciﬁc tolerance. Thus, current
protocols for IUHCT favor that the initial transplant be delivered by 12 weeks gestation within a
“therapeutic window” that opens shortly after prenatal diagnosis and closes with thymic matura-
tion (Westgren, 2006). Observations of naturally occurring hematopoietic chimeras demonstrates
that, in essence, this is feasible (Owen, 1945). However, repeated clinical failure of IUHCT in the
setting of a non-defective immune system has forced a re-examination of this central dogma, i.e.,
the translation of bedside observations back to the bench for hypothesis-driven inquiry.
The Clinical Paradigm for Prenatal Transplantation
Two related observations arising from clinical experience with IUHCT are in need of a scientiﬁc
explanation. First, clinical application of IUHCT has documented success in the treatment of severe
combined immunodeﬁciency (SCID). Indeed, the greatest clinical success has been realized in the
treatment of NK cell deﬁcient SCID (xSCID or ADA-SCID) whereas the use of IUHCT for the
treatment of congenital diseases in which the fetal immune system is not defective has been uni-
formly unsuccessful (Touraine et al., 1992; Flake et al., 1996; Wengler et al., 1996) This includes
most of the clinical experience with IUHCT for hemoglobinopathies such as sickle cell disease
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or thalassemia. Second, the maternal immune system has been
intact for every case despite the nature of the clinical outcome
(success or failure) suggesting no independent role for the mater-
nal immune response in IUHCT-related engraftment failures.
Taken together, these observations frame the clinical paradigm
for IUHCT and serve as a template for translational study.
It has been postulated that competition between the donor
and recipient cells for a limited number of available host
hematopoietic stem cell (HSC) niches is responsible for the
clinical failure of IUHCT in the treatment of hemoglobinopa-
thy (Peranteau et al., 2004, 2006). Favorable competition with
the host cells for available niches within the fetal liver or
bone marrow is vital for successful engraftment and likely
explains the enhanced clinical and experimental success of
IUHCT with the use of more competitive fetal donor cells
or larger doses of bone marrow cells (Shaaban and Flake,
1999; Peranteau et al., 2006; Shaaban et al., 2006). Improved
competition for available host niches would logically lead
to higher levels of early chimerism. Previous reports from
our group illustrate that the early chimerism level (discussed
below) is the major determinant of successful allogeneic
engraftment and link this to the development of donor-
speciﬁc NK cell tolerance (Shaaban et al., 2006; Durkin et al.,
2008a,b; Alhajjat et al., 2013). However, a competitive-niche
model struggles to explain the dichotomous observations for
immunodeﬁcient vs. non-immunodeﬁcient cases and seems
to disregard the obvious diﬀerence. More speciﬁcally, no
direct evidence exists to support the existence of quantita-
tive diﬀerences in the number of HSCs or available stem
cell niches between the xSCID and sickle cell disease or β-
thalassemia patients. To the contrary, the defects in SCID
emerge following the lineage-speciﬁc diﬀerentiation of HSCs
rather than during their maintenance or self-renewal (reviewed
in Schmalstieg and Goldman, 2002; Kalman et al., 2004) As a
result, the pre-thymic SCID fetal hematopoietic microenviron-
ment should theoretically have the same frequency of available
stem cell niches as in pre-thymic fetus with defective β-globin
production and should engraft similarly if niche availability is
the limiting factor. Therefore, a model in which donor cell
competition for host niches solely determines the outcome of
IUHCT does not adequately reconcile the clinical paradigm
and prompts further study of early gestation fetal alloimmu-
nity.
Studies in murine and primate models of IUHCT support
the presence of an early gestation immune barrier to allotrans-
plantation (Peranteau et al., 2007; Durkin et al., 2008a,b). In a
murine study by Peranteau et al. (2007), both congenic and allo-
geneic transplant recipients demonstrated similar multi-lineage
engraftment at 1 week of age. Thereafter, most allogeneic recipi-
ents lost engraftment (Peranteau et al., 2007). Similarly, we have
also demonstrated that congenic recipients maintain long-term
engraftment regardless of the chimerism level whereas allogeneic
recipients require a minimum level of circulating chimerism to
maintain stable engraftment and prevent a chronic form of rejec-
tion (Durkin et al., 2008b). Lastly, despite promising results in
other large animal models (Lee et al., 2005; Vrecenak et al., 2014),
numerous studies of allogeneic IUHCT in non-human primates
have yield poor overall engraftment regardless of the gestational
age (Cowan et al., 1996; Shields et al., 2003, 2004). In general,
the use of fetal conditioning or mature T cell co-transplantation
resulted in higher engraftment rates and chimerism levels over-
all (Peranteau et al., 2002; Hayashi et al., 2004; Ashizuka et al.,
2006). Collectively, these ﬁndings point to the existence of a
previously unrecognized immune barrier to IUHCT that resides
within the fetal host potentially complicating the kinetics of early
engraftment.
Fetal T Cells are Unlikely to Act Alone
in Rejection after IUHCT
In the complexity of the developing fetus, successful prenatal
engraftment likely requires that all components of the immune
system develop tolerance. Similarly, failed engraftment in clin-
ical cases that do not involve immunodeﬁciency likely results
from a lack of tolerance in one or more components of the fetal
immune response. In either case, an intrinsic immune barrier
to prenatal allotransplantation exists within the fetal host and
awaits further delineation. In the greater context, a better under-
standing of the critical parameters regulating the emergence of
self-tolerance may explain the pattern of success and failure of
IUHCT.
Previous studies reveal that T cell self-recognition is estab-
lished before birth inmost strains of mice including the C57BL6/J
and Balb/c inbred strains. The ﬁrst measurable indicator of
self-recognition is the emergence of phenotypically mature T
cells as early as E17 (Crispe et al., 1986). Phenotypically mature
single-positive T cells have been found in the human thy-
mus as early as 12 weeks gestation (Stites and Pavia, 1979;
Haynes et al., 1989). Conﬁrmation of the functional capacity
to reject an allograft comes from transplant studies in new-
born mice which do not accept fully allogeneic hematopoi-
etic grafts without myeloablation or immunological preparation
(Soper et al., 2003). Conversely, the capacity to reject allogeneic
grafts does not exist earlier in gestation. The studies by Kim et al.
(1998, 1999) ﬁrst demonstrated that allospeciﬁc T cell toler-
ance can be reliably achieved by IUHCT to the murine fetus
at E14 resulting in the deletion and anergy of donor-reactive
T cells. Subsequent studies conﬁrmed the allo-receptivity of
C57BL/6 and Balb/c fetuses at E14 (Shaaban et al., 1999, 2006;
Hayashi et al., 2002;Durkin et al., 2008a,b; Alhajjat et al., 2013;
Nijagal et al., 2013). Collectively, these ﬁndings suggest that the
potential for donor-speciﬁc tolerance to reliably develop follow-
ing IUHCT is lost shortly after the appearance of mature single
positive T cells.
Furthermore, in the studies by Kim et al. (1998, 1999), T cell
and skin allograft tolerance could be seen with extremely low lev-
els of microchimerism (<0.1%) following IUHCT between MHC
class I-matched or mismatched strain combinations. These ﬁnd-
ings seem to conﬂict with subsequent studies (Ashizuka et al.,
2006; Durkin et al., 2008b) demonstrating that tolerance to a
hematopoietic graft tolerance requires macrochimerism (1–2%)
but may be reconciled through an understanding of the dif-
ferent measures of tolerance. Skin-graft acceptance has been
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shown to reﬂect T cell rather than NK cell tolerance whereas
tolerance to a hematopoietic graft reﬂects both. NK cells fail
to reject allogeneic skin grafts in the absence of IL-15 activa-
tion (Kroemer et al., 2008). Thus in sub-threshold microchimeric
mice, host T cells may be tolerant to allogeneic skin grafts
while host NK cells are not tolerant to allogeneic hematopoi-
etic cells. Additionally, although NK maturation occurs in the
early second trimester of human gestation, it continues for sev-
eral weeks after birth in the B6 mouse (Dorfman and Raulet,
1998). In the aforementioned studies by Kim et al. (1998, 1999),
the majority of skin grafts were placed on the microchimeric
mice during the prolonged phase of chronic rejection that is
typical of low-level prenatal chimerism. As such some degree
of hyporesponsiveness to skin and possibly hematopoietic grafts
likely exists during this rejection period. Comparative mea-
surements of the allospeciﬁc response between T cells and NK
cells in microchimeric or sub-threshold chimeric mice might
reveal these diﬀerences. Thus, the existence of hematopoietic
microchimerism during that period appears to be suﬃcient for
donor-speciﬁc T cell and skin allograft tolerance to develop
but insuﬃcient for NK cell tolerance. As such, the potential
for either T cell tolerance or rejection to develop following
IUHCT seems to hinge on the timing of transplant rather than
the level of chimerism. Perhaps these diﬀerences arise from
the relatively high-aﬃnity interactions between T cell recep-
tors and peptide-MHC complexes (TCR-pMHC) that regulate
much of thymic selection (reviewed in Moran and Hogquist,
2012; Morris and Allen, 2012). Given the high cell dose per
kg of fetal body mass previously used for clinical IUHCT, it
is likely that suﬃcient chimerism levels were present for the
induction of T cell tolerance. As such, T cell-mediated rejection
seems to be an inadequate stand-alone explanation for the failed
engraftment seen in the treatment of hemoglobinopathy by
IUHCT.
Fetal NK Cells as an Intrinsic Barrier to
Prenatal Allotransplantation and a
Target for Immunotherapy
The presence of a secondary barrier to prenatal engraft-
ment mediated by fetal NK cells would explain the clinical
pattern of enhanced success in NK cell deﬁcient recipients
(Flake et al., 1996; Wengler et al., 1996; Archer et al., 1997). An
NK cell barrier would also explain the delayed experimen-
tal engraftment loss (chronic rejection) previously reported
by multiple investigators (Carrier et al., 2000; Donahue et al.,
2001; Peranteau et al., 2007; Durkin et al., 2008b) as this coin-
cides temporally with the maturation of NK cell allorecog-
nition (Roth et al., 2000). For these reasons, we queried the
response of NK cells in a murine model and ultimately con-
ﬁrmed the existence of an NK cell-mediated barrier to the
engraftment of prenatally transplanted allogeneic hematopoi-
etic cells (Figure 1). Importantly, this barrier was found to
be critically dependent on the level of circulating chimerism
(Durkin et al., 2008b). With high levels of chimerism, recip-
ients maintained stable engraftment and exhibited donor-
speciﬁc NK cell tolerance. Conversely, recipients with low
chimerism levels displayed NK cell-dependent chronic graft
rejection.
The essence of this quantitative model for NK cell education
is that the donor-speciﬁc tolerance requires a threshold level of
FIGURE 1 | The outcome of engraftment or rejection following
allogeneic In utero hematopoietic cellular transplantation (IUHCT) is
predicted by the early chimerism level and hinges on the development
of NK cell tolerance. (A) Mice with an early chimerism level above the
chimerism threshold (Engrafter mice; >1.8% circulating chimerism) exhibit
durable long-term multi-lineage engraftment. (B) With early chimerism levels
below the chimerism threshold, NK cell tolerance does not develop and
universal rejection occurs (Rejecter mice; <1.8% circulating chimerism).
(C) Rejection is abrogated when NK cells are depleted in rejecter mice thereby
rescuing prenatal engraftment (Rescued Engrafter mice).
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exposure to the donor ligands during development – a chimerism
threshold (>1.8%). Remarkably, we found that the chimerism
threshold reliably predicts the binary outcome of either engraft-
ment or rejection which is the arguably most meaningful measure
of prenatal tolerance induction. Furthermore, the chimerism
threshold proved to be irrelevant in IUHCT between congenic
strains of mice which are immunologically matched reducing
the likelihood that limiting-dilution kinetics were the cause of
failed engraftment below the chimerism threshold (Durkin et al.,
2008b). Lastly, we demonstrated that the engraftment loss can
be prevented in sub-threshold chimeras by early in vivo deple-
tion of host NK cells (Figure 1). During the period of NK cell
depletion, chimerism levels remained stable or increased slightly.
When the host NK cells were allowed to return following with-
drawal of the depleting antibody, abrupt rejection was observed
in all of the animals. These ﬁndings deﬁned a critical relation-
ship between a threshold level of donor chimerism and the
development of donor-speciﬁc NK cell tolerance. In a larger
context, the signiﬁcance of this threshold lies in the identiﬁca-
tion of the minimum level of antigen exposure during the T
and NK cell education that is necessary for durable recognition
as self.
Trogocytosis as a Mechanistic Link
between the Chimerism Threshold and
Prenatal NK Cell Tolerance
In order for prenatal tolerance to develop at such low
levels of chimerism (1.8%), the process of self-education
should include a mechanism to compensate for the low
probability of eﬀector cells to encounter appreciable lev-
els of donor ligand. We have recently reported that donor-
to-host MHC transfer (trogocytosis) might function in this
role (Alhajjat et al., 2013). Trogocytosis of donor MHC may
permit sustained cis-recognition of the donor ligands dur-
ing development in the absence of trans-interaction directly
with the donor cells or with host APC’s. The cis-recognition
of donor antigens by tolerant host NK cells may selectively
prevent the apoptosis of “friendly” phenotypes during the
selection of the mature NK cell repertoire. Support for this
mechanism comes from the recent report by Brodin et al.
(2012) who examined Ly49D+ NK cells in H-2Dd transgenic
B6 mice and found that the co-expression of Ly49A con-
ferred a resistance to apoptosis. Consistent with this postulate,
high levels of trogocytosis were found on the surface of
phenotypically friendly NK cells that express donor-speciﬁc
inhibitory receptors when compared to the phenotypically hos-
tile NK cells that do not express these inhibitory receptors.
Subsequent to their developmental selection, the cis-recognition
of transferred donor-MHC by phenotypically friendly NK cells
might provide a continuous exposure to the donor ligands
aﬀecting their maturation, survival and function (Kim et al.,
2005; Chalifour et al., 2009). In this manner, trogocytosis of
donor ligands could provide an intrinsic mechanism for
the development and maintenance of donor-speciﬁc NK cell
tolerance.
Fetal NK Cells at the Interface with the
Maternal Immune System
A maternal immune response toward the donor cells has been
proposed as a barrier to prenatal allo-transplantation resulting in
the delayed chronic rejection of the donor graft (Merianos et al.,
2009; Nijagal et al., 2011). As discussed earlier, this postulate is
inconsistent with the recurring clinical observation that IUHCT
has been successful in cases where the maternal immune response
was intact but the fetal immune system was defective (Flake et al.,
1996; Wengler et al., 1996; Merianos et al., 2008). Also incom-
patible with this conclusion is the observation that engraftment
or rejection after IUHCT occurs in littermates subjected to the
same maternal inﬂuence (Durkin et al., 2008b; Merianos et al.,
2009). Lastly, the in vivo elimination of host NK cells prevents the
chronic rejection seen in sub-threshold chimeras and establishes
that the eﬀectors of this response reside within the fetal recipient.
Collectively, these ﬁndings argue against the existence of a clin-
ically relevant maternal immune barrier to IUHCT and should
be reconciled with those of previous reports concluding that a
maternal immune response toward the transplanted cells leads to
engraftment loss in allogeneic IUHCT.
In the study by Merianos et al. (2009), prenatal allogeneic
chimeras were noted to lose engraftment at a relatively high rate
several weeks after birth. When naïve foster dams were used
after delivery, no engraftment loss occurred. This observation
was explained by the ﬁnding of donor-speciﬁc alloantibodies in
the maternal breast milk that perhaps induced graft rejection
after birth. The authors provided no data regarding the level of
chimerism in the animals that rejected their graft. Additionally,
the presence of maternal alloantibodies did not result in graft
rejection in nearly 1/3 of the littermates of the pups that lost
engraftment suggesting some heterogeneity in the eﬀect of the
maternal immune response.
These ﬁndings may relate to the experimental methodol-
ogy employed in their study. The study by Merianos et al.
(2009) used very large doses of adult donor bone marrow cells
(20 × 106cells/fetus) which provided a large number of mature
T cells to the fetus (approximately 109 mature T cells/kg). These
large T cell doses may have resulted in a signiﬁcant graft-vs-host
reaction that may have diminished the maternal–fetal immune
barrier leading to a greater exposure of the fetal cells to the mater-
nal immune system. The high chimerism levels seen in this model
likely compounded the exposure to the donor alloantigens lead-
ing to a functionally signiﬁcant maternal immune response and
precipitous fetal loss. Conversely, mature T cells are absent from
the fetal liver donor cell populations used in other studies and
chimerism levels are much more modest at the lower doses that
were used (Rebel et al., 1996; Szilvassy et al., 2001; Taylor et al.,
2002; Hayashi et al., 2003). Further study is necessary to conﬁrm
the potential to provoke a maternal humoral response with the
use of large T cell doses or high early chimerism levels in IUHCT.
These possibilities are further supported by the study of
Nijagal et al. (2011), which utilized fetal liver cells for prena-
tal transplantation and found that the use of naïve foster dams
had no impact on delayed engraftment loss. Instead, the authors
observed that a signiﬁcant numbers of T cells traﬃc from the
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mother into the fetus following prenatal transplantation and pro-
posed that a maternal T cell response was responsible for the
lower early engraftment rates in allogeneic vs. congenic IUHCT.
Indeed, higher engraftment rates were seen with the use of T
cell deﬁcient mothers or by matching the donor cells with the
maternal MHC antigens in wild-type matings thereby avoiding
the potential for a maternal T cell response in either setting.
However, the reported early engraftment rate in this study is
unusually low given the relatively large number of transplanted
fetal liver cells. Using the same methodology to prepare and
prenatally transplant a similar dose of MHC mismatched fetal
liver donor cells (2 × 106 cells/fetus) in this strain combina-
tion, we have reliably detected engraftment in 100% of the oﬀ-
spring despite the use of immunologically normal wild-type dams
(Durkin et al., 2008b). The reasons for the diﬀerent engraftment
rates between the two studies are unclear but may result from dif-
ferences in the strain combination or technical variations in the
transplant procedure. Additionally, the authors concluded that
maternal T cells persisted in the chimeric oﬀspring for months
after birth and led to chronic rejection. However, no maternal
cells could be found within the recipient at any point beyond the
fetal period making it diﬃcult to reconcile engraftment loss by
this mechanism that occurred months later. Despite these unre-
solved issues, the ﬁnding of maternal cells in the fetal immune
system illustrates the potential complexities involved in prenatal
transplantation and clearly warrants further study.
Early Gestation Human Fetal NK Cells
Possess the Capacity for
Allorecognition and the Potential to
Respond to Prenatal
Allo-Transplantation
The gestational time frame in which human fetal NK cells develop
the capacity for allorecognition has not been directly eluci-
dated. The ﬁnding of mature cytotoxic NK cells in human cord
blood provides clear evidence that this occurs prior to birth
(Wang et al., 2007). It is conceivable that this coincides with
acquisition of killer immunoglobulin-like receptors (KIR) simi-
lar to the acquisition of the homologous Ly49 NK cell receptors
in mice (Roth et al., 2000). Acquisition of Ly49 receptors is com-
mensurate with development of mature cytotoxic capacity and
temporally coincides with rejection in sub-threshold chimeras
or tolerance and engraftment in above threshold chimeras
(Anfossi et al., 2006; Durkin et al., 2008b; Orr and Lanier, 2010).
In a seminal report by Phillips et al. (1992), NK cells were found
in human fetal liver as early as 6 weeks and in fetal spleen by
15 weeks of gestation. Similar to observations in fetal mice, these
early human fetal liver NK cells were found to express high lev-
els of the class Ib-speciﬁc CD94/NKG2 receptors. However, an
analysis for the expression of the class Ia-speciﬁc KIR receptors
was not included. The in vitro study of diﬀerentiating CD34+
hematopoietic progenitors indicates that CD94/NKG2A expres-
sion precedes the expression of HLA-speciﬁc KIR receptors by
human NK cells (Grzywacz et al., 2006). For this reason, we
examined the expression of KIR receptors by early gestation
human fetal NK cells and found that small subsets of human fetal
NK cells express adult levels of KIR receptor by 10 weeks of ges-
tation with more appreciable levels identiﬁed by 14 weeks gesta-
tion (Alhajjat et al., 2010). A subsequent report by Ivarsson et al.
(2013), demonstrated paradoxical hyporesponsivness to KIR-
speciﬁc stimulation of second trimester human fetal NK cells.
Hence, although early gestation human fetal NK cells possess the
necessary machinery for allorecognition, a conﬁrmation of their
capacity for allospeciﬁc cytotoxicity requires future study.
Closing Remarks
Successful engraftment in IUHCT likely requires tolerance in
all components of the host immune system. Our studies in the
murine model have indicated that a minimum level of circulat-
ing ligand is necessary to induce and maintain tolerance. This
level seems to be higher for NK cells than the level required for
other components of the immune system. Thus, the chimerism
threshold might represent the minimum qualiﬁcation in the
education of the developing NK cells and NK cell tolerance as
the ﬁnal endorsement of donor recognition. The study of NK
cell repertoire formation, maturity, and trogocytosis in prenatal
transplantation will not only facilitate understanding of the NK
cell barrier, but will also contribute to the overall understanding
of NK cell biology.
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